Representatives from insulin manufacturers blamed a system that requires them to pay higher and higher rebates to pharmacy-benefit managers to gain access to the patients whose prescriptions the PBMs manage.
Decisions by two of the world's biggest insulin producers to offer bigger discounts on drugs used by millions of diabetics are raising questions from Congress about whether the companies could have done so sooner.
On Wednesday, French drugmaker Sanofi said it would increase discounts on insulin for some patients. The move follows recent efforts by Cigna Corp., which runs a major drug plan, and Eli Lilly & Co., another major insulin producer, to lower patients' out-of-pocket costs for the drugs.
Continue Reading for Free
Register and gain access to:
- Breaking benefits news and analysis, on-site and via our newsletters and custom alerts
- Educational webcasts, white papers, and ebooks from industry thought leaders
- Critical converage of the property casualty insurance and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
Already have an account? Sign In Now
© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
